Glioma-associated antigens targeted by immunotherapeutic approaches include cell adhesion molecules, matrix proteins, and growth factor receptors, such as tenascin [6], wild-type epidermal growth factor receptor [7], its glioma-associated variant, epidermal growth factor receptor variant III [5,8], and GPNMB [9]. The gene discussed is TNC; the disease is glioma.